Eris Lifesciences has released its investor presentation for the second quarter (Q2) and first half (H1) of the financial year 2027. The presentation highlights financial performance, including revenue growth of 14.1% YoY in Q2 FY27 and a PAT growth of 39.2% for the same quarter. Key business updates on Domestic Branded Formulations (DBF), International Business, and Consolidated Financials are detailed.
Eris Lifesciences Presents Q2 & H1 FY27 Financials
Eris Lifesciences Limited has submitted its investor presentation for the fiscal period ending September 30, 2026, covering results for Q2 and H1 FY27. The company reported a revenue growth of 14.1% Year-over-Year (YoY) in Q2 FY27, with an EBITDA margin of 35.7%. For the half-year (H1 FY27), the company saw a revenue growth of 14.2%.
Key Financial Highlights
The Domestic Branded Formulations (DBF) segment reported a 14.1% YoY growth in Q2 FY27 to Rs. 809 crore. DBF EBITDA for Q2 FY27 was Rs. 288 crore, a +8.3% increase, with a margin of 35.7%. For H1 FY27, DBF revenue reached Rs. 1,610 crore, growing 14.2% YoY, and EBITDA was Rs. 567 crore, up +7.5% with a margin of 35.2%.
Consolidated financials for Q2 FY27 show revenue at Rs. 892 crore, a 12.6% growth YoY, and Profit After Tax (PAT) at Rs. 187 crore, a significant 39.2% increase YoY. For H1 FY27, consolidated revenue was Rs. 1,766 crore (12.8% growth YoY) and PAT was Rs. 330 crore (27.3% growth YoY).
Business Segment Performance
The Domestic Branded Formulations (DBF) segment’s therapy mix shows 73% from Chronic therapies. The company’s brands are categorized by annual revenue, with 3 brands above ₹200 crore in size contributing to 44% of revenue from the top 10 brands.
The International Business, specifically Swiss Parenterals, reported flat revenue growth for Q2 FY27 at Rs. 83 crore, while H1 FY27 revenue stood at Rs. 155 crore (2.3% growth). The EBITDA margin for Swiss Parenterals in Q2 FY27 was 25.0%.
Strategic Updates and Outlook
The presentation also details the Zorvia Deal, involving licensed injectables and a 7% royalty for Eris. The company expects a ~100 bps Gross Margin improvement ex-Zorvia. Key levers for gross margin improvement include brands out-licensed to Zorvia and the commercialization of the Bhopal facility.
In the Diabetes therapy segment, Eris contributes 37.3% to the portfolio and saw a growth of 18.5% in Q2 FY27, outperforming the IPM growth of 16.1%. The company is advancing its diabetes pipeline, including trials for India’s first Recombinant Semaglutide.
Consolidated highlights for H1 FY27 include a ROCE of 19% and a net debt reduction of ~111 crore. Capex cycle is winding down by the end of FY27. The company also noted Consolidated Debtor days at 70 in Sep’ FY27, a reduction of 10 days from Mar’ FY26.
Source: BSE
